Literature DB >> 24900360

Synthesis and Cardiac Imaging of (18)F-Ligands Selective for β1-Adrenoreceptors.

Heike S Radeke1, Ajay Purohit1, Thomas D Harris1, Kelley Hanson1, Reinaldo Jones1, Carol Hu1, Padmaja Yalamanchili1, Megan Hayes1, Ming Yu1, Mary Guaraldi1, Mikhail Kagan1, Michael Azure1, Michael Cdebaca1, Simon Robinson1, David Casebier1.   

Abstract

A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood pool into the myocardium (0.48-0.62% ID/g), lung (0.63-0.97% ID/g), and liver (1.03-1.14% ID/g). Dynamic μPET imaging confirmed the in vivo dissection studies.

Entities:  

Keywords:  18F-labeling; PET; cardiac imaging; heart failure; β1-selective ligand

Year:  2011        PMID: 24900360      PMCID: PMC4018132          DOI: 10.1021/ml1002458

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  22 in total

Review 1.  PET and SPET tracers for mapping the cardiac nervous system.

Authors:  Oliver Langer; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03       Impact factor: 9.236

2.  Preclinical evaluation of an 18F-labelled beta1-adrenoceptor selective radioligand based on ICI 89,406.

Authors:  Marilyn P Law; Stefan Wagner; Klaus Kopka; Christiane Renner; Victor W Pike; Otmar Schober; Michael Schäfers
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

3.  Myocardial beta-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388.

Authors:  Richard M de Jong; Antoon T M Willemsen; Riemer H J A Slart; Paul K Blanksma; Aren van Waarde; Jan Hein Cornel; Willem Vaalburg; Dirk J van Veldhuisen; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-11       Impact factor: 9.236

4.  Clinical, electrocardiographic, and hemodynamic effects of ICI 89,406, a new cardioselective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity, in patients with angina pectoris.

Authors:  P A Majid; J E Schreuder; P J de Feyter; J P Roos
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jul-Aug       Impact factor: 3.105

Review 5.  Fundamental considerations of beta-adrenoceptor subtypes in human heart failure.

Authors:  Peter Molenaar; William A Parsonage
Journal:  Trends Pharmacol Sci       Date:  2005-07       Impact factor: 14.819

Review 6.  Cardiac adrenoceptors: physiological and pathophysiological relevance.

Authors:  Otto-Erich Brodde; Heike Bruck; Kirsten Leineweber
Journal:  J Pharmacol Sci       Date:  2006-04-13       Impact factor: 3.337

7.  Alterations in cardiac alpha and beta adrenoceptors during the development of spontaneous hypertension.

Authors:  S Yamada; T Ishima; T Tomita; M Hayashi; T Okada; E Hayashi
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

8.  Design of new beta1-selective adrenoceptor ligands as potential radioligands for in vivo imaging.

Authors:  Klaus Kopka; Stefan Wagner; Burkhard Riemann; Marilyn P Law; Carsten Puke; Sajinder K Luthra; Victor W Pike; Thomas Wichter; Wilhelm Schmitz; Otmar Schober; Michael Schäfers
Journal:  Bioorg Med Chem       Date:  2003-08-05       Impact factor: 3.641

9.  Are [O-methyl-11C]derivatives of ICI 89,406 beta1-adrenoceptor selective radioligands suitable for PET?

Authors:  Marilyn P Law; Stefan Wagner; Klaus Kopka; Victor W Pike; Otmar Schober; Michael Schäfers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-29       Impact factor: 9.236

10.  New approach for the synthesis of [18F]fluoroethyltyrosine for cancer imaging: simple, fast, and high yielding automated synthesis.

Authors:  M Zuhayra; A Alfteimi; C Von Forstner; U Lützen; B Meller; E Henze
Journal:  Bioorg Med Chem       Date:  2009-09-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.